Immunosuppression Clinical Trial
Official title:
Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)
Verified date | January 2017 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will examine the safety and effectiveness of a monoclonal antibody called
humanized anti-Tac (HAT, also called daclizumab) to treat children and adolescents with
uveitis (chronic inflammatory eye disease) associated with juvenile idiopathic arthritis
(JIA). Monoclonal antibodies are genetically engineered proteins made in large quantities
and directed against a specific target in the body. The HAT antibody is designed to prevent
a specific chemical interaction needed for immune cells to produce inflammation. Current
treatments for uveitis include steroids and immune-suppressing drugs. These treatments do
not always work or they may cause significant side effects. This study will determine
whether daclizumab can improve uveitis in children and reduce the need for other medicines.
Patients between 6 and 18 years of age with active non-infectious JIA-associated uveitis
requiring treatment with anti-inflammatory medications as often as three times a day or more
may be eligible for this study.
Each candidate is screened with a medical history, physical examination, blood tests, eye
examination, and the following specialized tests:
- Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected
into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina
are taken using a camera that flashes a blue light into the eye. The pictures show if
any dye has leaked from the vessels into the retina, indicating the presence of
inflammation.
- Optical coherence tomography to measure retinal thickness. The eyes are examined
through a machine that produces cross-sectional pictures of the retina. These measures
are repeated during the study to determine changes, if any, in retinal thickening.
- Stereoscopic color fundus photography to examine the back of the eye. The pupils are
dilated with eye drops to examine and photograph the back of the eye.
Upon entering the study, participants receive a 90-minute infusion of daclizumab through a
catheter (plastic tube) placed in an arm vein. They return to the clinic after 14 days and
again after 28 days for repeat eye examinations, blood tests, and daclizumab infusions. Four
weeks after the third infusion, patients are examined for response to treatment. Those who
have benefited from daclizumab may continue receiving monthly infusions of the drug for up
to one year. A blood test and eye examination are done at the time of each infusion.
Patients whose disease has remained active 12 weeks after the first infusion are taken off
the study and treated with other medications.
Status | Completed |
Enrollment | 6 |
Est. completion date | May 2008 |
Est. primary completion date | May 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Participant is from 6 to 18 years of age, inclusive; 2. Participant has a diagnosis of non-infectious uveitis associated juvenile idiopathic arthritis (JIA) requiring treatment to control their intraocular inflammatory disease with anti-inflammatory medications, systemic and/or topical at high frequency intervals (greater than or equal to 3 times a day). 3. Participant's uveitis is considered active on current regimen 4. Participant has uveitis with at least a grade of 1+ for anterior chamber cells in at least one eye 5. Participant's uveitis is currently treated or untreated at the time of enrollment 6. Participant has visual acuity in at least one eye of 20/640 or better (Early Treatment Diabetic Retinopathy Study (ETDRS) or Electronic Visual Acuity-Amblyopia Treatment Study (EVA-ATS), log minimum angle of resolution (logMAR) less than 1.54). 7. Participant has normal renal or liver function or evidence of no worse than mild abnormalities as defined by the "Common Toxicity Criteria for Adverse Events" (CTCAE) version 3.0, including: Test Parameter Age (yrs) Pediatric Mild Limit Serum creatinine 6-12 1.0 mg/dL 13-18 1.6 mg/dL Proteinuria 6-18 3 g/L Uric acid 6-18 9.9 mg/dL Blood Urea Nitrogen (BUN) 6-18 2.0 upper normal limit Aspartate aminotransferase (Serum glutamic-oxaloacetic transaminase) (AST (SGOT)) 6-18 2.5 upper normal limit Alanine aminotransferase (Serum glutamic pyruvic transaminase) (ALT (SGPT)) 6-18 2.5 upper normal limit 8. Participant agrees not to undergo elective ocular surgery (e.g., cataract extraction) for the first 6 months of the study. 9. Participant has an absolute neutrophil count above 750. 10. Participant is not currently pregnant or lactating. 11. Participant with reproductive potential and who is sexually active agrees to use acceptable birth control methods throughout the course of the study and for 6 months after completion of treatment. 12. All participants at enrollment has a parent or legal guardian who is able to understand and sign a consent form on their behalf before entering into the study, and participant signs an assent as a minor. 13. Meet American College of Rheumatology Criteria for Juvenile Rheumatoid Arthritis (JRA)/JIA (Appendix) but is not newly diagnosed, and has had systemic treatment for their uveitis. 14. Be able to undergo slit lamp biomicroscopy for assessment of anterior chamber cells. 15. Be able to comply with the study requirements. 16. Be up to date on all recommended childhood immunizations. EXCLUSION CRITERIA: 1. Participants under the age of 6 years will not be enrolled in the study due to the reported higher incidence of adverse events related or unrelated to the administration of daclizumab in post-transplant pediatric studies compared to children over age 6. 2. Participants who had received previous treatment with an IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety, efficacy or pharmacokinetics of daclizumab. 3. Participants with a history or diagnosis of Behcet's disease. 4. Participant has a significant active infection. 5. Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past 5 years. 6. Participant has used latanoprost (Xalatan) within two weeks prior to study enrollment or has a likely need. 7. Participant for whom administration of fluorescein dye is medically contraindicated. 8. Have a media opacity that precludes assessment of anterior chamber inflammation. 9. Be a female who is pregnant or lactating. 10. Refuse to use contraception during the study and 6 months after termination of active study therapy, if child-bearing or fathering potential exists. 11. Have active serious infections or a history of recurring serious infections. 12. Evidence of spondyloarthropathy or enthesopathy. 13. Have active joint or systemic inflammation requiring immediate addition or increase in systemic anti-inflammatory medications. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Eye Institute (NEI) | The EMMES Corporation |
United States,
Chylack LT Jr. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977 Mar;20(2 Suppl):217-23. — View Citation
Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, Ryan JG, Hammel K, Nussenblatt RB. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009 Nov;148(5):696-703.e1. doi: 10.101 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With a Two-step Reduction in Inflammation | Number of participants with a two-step reduction (or down to 0 out of a scale of 0 to 4+) of anterior chamber (AC) inflammation according to Standardization of Uveitis Nomenclature (SUN) criteria, while on a topical corticosteroid schedule of less than 3 times a day. Grade 0 is the best score on this scale with <1 cell in the field and 4+ is the worst score on this scale with >50 cells in the field. | 12 weeks | |
Primary | Number of Participants Reporting a Serious Adverse Event (SAE) | Safety of acute daclizumab use in JIA-associated uveitis was assessed through serious adverse events (SAE). | 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT01252537 -
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
|
N/A | |
Completed |
NCT01678937 -
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
|
N/A | |
Completed |
NCT00621699 -
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00788021 -
Protective Immunity Project 01
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT05616130 -
Pathological Myeloid Activation After Sepsis and Trauma
|
||
Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
Recruiting |
NCT01568697 -
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
|
||
Not yet recruiting |
NCT06024226 -
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
|
||
Not yet recruiting |
NCT04961229 -
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
|
Phase 4 | |
Completed |
NCT03139565 -
High Dose vs. Standard Influenza Vaccine in Adult SOT
|
Phase 3 | |
Completed |
NCT02547753 -
Dental Extractions Among Renal Transplant Recipients
|
||
Completed |
NCT01702207 -
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
|
Phase 4 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00419575 -
Renal Transplantation With Immune Monitoring
|
N/A | |
Completed |
NCT00783380 -
Influenza Vaccination in Immunocompromized Patients
|
Phase 4 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Recruiting |
NCT05043870 -
Combined Immunosuppression for Pediatric Crohn's Disease
|
Phase 4 |